Program
letetresgene autoleucel
Also written as “Letetresgene autoleucel”, “letetresgene autoleucel (GSK3377794)” and “Letetresgene autoleucel (Lete-Cel (GSK3377794))”.
Its studies are mostly in Neoplasms · Liposarcoma, Myxoid · Multiple Myeloma · Carcinoma, Non-Small-Cell Lung · Sarcoma, Synovial, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 40 open or running | phase 2since Dec 12, 2016 | Oct 26, 2015 | none ahead |
| USWM CT | 21 open or running | phase 2since May 10, 2019 | May 10, 2019 | none ahead |
| USWM, LLC (dba US WorldMeds) | 10 open or running | phase 2since Aug 7, 2023 | Aug 7, 2023 | none ahead |
Also a collaborator on its studies: Merck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 26, 2015First study: phase 1 study in NeoplasmsNew to GlaxoSmithKlineGlaxoSmithKline · NCT02588612 · 10 enrolled · United States
- Dec 12, 2016Phase 2 study in NeoplasmsGlaxoSmithKline · NCT02992743 · 23 enrolled · United States
- May 24, 2017Phase 1 study in NeoplasmsGlaxoSmithKline · NCT03168438 · 6 enrolled · United States
- Oct 4, 2018Phase 2 study in NeoplasmsGlaxoSmithKline · NCT03697824
- May 10, 2019USWM CT’s first study: phase 2 study in NeoplasmsNew to USWM CTUSWM CT · NCT03967223 · 103 enrolled · United States, Canada, France and more
- Aug 7, 2023USWM, LLC (dba US WorldMeds)’s first study: phase 2 study in NeoplasmsNew to USWM, LLC (dba US WorldMeds)USWM, LLC (dba US WorldMeds) · NCT05993299 · 7 enrolled · United States, Canada, France and more
- Nov 21, 2024Phase 2 study in NeoplasmsUSWM CT · NCT06703346 · 82 enrolled · United States, Canada, France and more
TargetBeta
“Human autologous T-lymphocytes transduced with a lentiviral vector encoding a T-cell receptor (TCR) specific for the cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 (LAGE-1; Cancer/Testis Antigen 2; CTAG2; CT2), ”NCIt, by rule
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06703346Neoplasms · United States, Canada, France and more | 2 | Completed | USWM CT | Mar 1, 2024 | 82 |
| NCT05993299Neoplasms · United States, Canada, France and more | 2 | Completed | USWM, LLC (dba US WorldMeds) | Oct 12, 2022 | 7 |
| NCT03967223Neoplasms · United States, Canada, France and more | 2 | Active, not recruiting | USWM CT | Mar 1, 2024 | 103 |
| NCT03697824Neoplasms | 2 | Withdrawn | GlaxoSmithKline | Jul 18, 2022 | 0 |
| NCT03168438Neoplasms · United States | 1 | Terminated | GlaxoSmithKline | Jul 13, 2020 | 6 |
| NCT02992743Neoplasms · United States | 2 | Completed | GlaxoSmithKline | Nov 1, 2021 | 23 |
| NCT02588612Neoplasms · United States | 1 | Completed | GlaxoSmithKline | Aug 10, 2020 | 10 |
How it is read
Names in the registry
- “Letetresgene autoleucel”, 2 entries
- “letetresgene autoleucel (GSK3377794)”, 2 entries
- “Letetresgene autoleucel (Lete-Cel (GSK3377794))”, 1 entry
- “Letetresgene autoleucel (lete-cel, GSK3377794)”, 1 entry
- “Letetresgene autoleucel with pembrolizumab”, 1 entry
Conditions, from the studies’ own filings
- Neoplasms, 3 studies
- Liposarcoma, Myxoid, 1 study
- Multiple Myeloma, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Sarcoma, Synovial, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.